PPARA and cancer: The example of PPARβ/δ agonists which had been in clinical trials for the treatment of hyperlipidemia and cardiovascular diseases at the beginning of 2000 and turned out to provoke cancers in mice and rats after prolonged treatment, which put a stop to phase 4 trials [268], clearly illustrates the necessity of considering the therapeutic modulation of any PPAR with great care.